Pre‐ and post‐engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients
- 1 March 2005
- journal article
- Published by Wiley in Transplant Infectious Disease
- Vol. 7 (1) , 11-17
- https://doi.org/10.1111/j.1399-3062.2005.00088.x
Abstract
We report on bloodstream infection (BSI) rates, risk factors, and outcome in a cohort of 298 adult and pediatric hematopoietic stem cell transplantation (HSCT) recipients at Memorial Sloan-Kettering Hospital from September 1999 through June 2003. Methods. Prospective surveillance study. BSI rates are reported per 10,000 HSCT days. Date of engraftment is defined as the first of at least 3 consecutive dates of absolute neutrophil count >500/mm(3) after stem cell infusion. BSI severity grades: severe (intravenous antibiotics), life threatening (sepsis), or fatal (caused or contributed to death). Results. The incidence of pre- and post-engraftment BSI was 22% and 19.5%, respectively. Pre-engraftment highest rates were observed for viridans streptococci (58), Enterobacteriaceae (39), and Enterococcus faecium (34). Post-engraftment rates ranged from 0.2 to 2.9 without any predominant pathogen. In multivariate analyses, pre-engraftment BSI was associated with diagnosis of chronic myelogenous leukemia, age >18 years and peripheral blood stem cell graft; post-engraftment BSI was associated with acute graft-versus-host disease, neutropenia, and liver or kidney dysfunction. Attributable mortality was 12.5% and 1.7% for pre- and post-engraftment BSI, respectively. BSI fatality rates were 24% for viridans streptococci, 8% for E. faecium, 11% for Staphylococcus aureus, and 67% for Candida. Conclusions. Pre-engraftment BSI, especially by viridans streptococci and E. faecium, was associated with substantial attributable mortality. Post-engraftment BSI was a marker of post-transplant complications and rarely the primary cause of death.Keywords
This publication has 25 references indexed in Scilit:
- Current Trends in the Epidemiology of Nosocomial Bloodstream Infections in Patients with Hematological Malignancies and Solid Neoplasms in Hospitals in the United StatesClinical Infectious Diseases, 2003
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- An Outbreak of Vancomycin-Dependent Enterococcus faecium in a Bone Marrow Transplant UnitClinical Infectious Diseases, 1999
- Infections in adults undergoing unrelated donor bone marrow transplantationBritish Journal of Haematology, 1999
- Viridans streptococcal shock in bone marrow transplantation patientsAmerican Journal of Hematology, 1993
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationNew England Journal of Medicine, 1992
- Gram-positive bacteraemia in granulocytopenic cancer patientsEuropean Journal of Cancer and Clinical Oncology, 1990
- Vancomycin, Ticarcillin, and Amikacin Compared with Ticarcillin-Clavulanate and Amikacin in the Empirical Treatment of Febrile, Neutropenic Children with CancerNew England Journal of Medicine, 1988
- MUCOSITIS AND α-STREPTOCOCCAL SEPSIS IN BONE MARROW TRANSPLANT RECIPIENTSThe Lancet, 1984
- DECREASED INCIDENCE OF VIRIDANS STREPTOCOCCAL SEPTICAEMIA IN ALLOGENEIC BONE MARROW TRANSPLANT RECIPIENTS AFTER THE INTRODUCTION OF ACYCLOVIRThe Lancet, 1984